Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - ImmunoPrecise Antibodies

Next Previous
Drug Profile

Coronavirus vaccine - ImmunoPrecise Antibodies

Alternative Names: SARS-CoV-2 Vaccine - ImmunoPrecise Antibodies

Latest Information Update: 28 Mar 2024

Print Profile Download Citation

At a glance

  • Originator ImmunoPrecise Antibodies
  • Class COVID-19 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Injection)
  • 14 Dec 2020 Immunogenicity and adverse event data from a preclinical studies in COVID-2019 infections released by ImmunoPrecise antibodies and LiteVax
  • 25 Sep 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Injection)

Development Overview

Introduction

Coronavirus vaccine against SARS-CoV-2 coronavirus is being developed by ImmunoPrecise Antibodies, for the treatment and prevention of COVID-2019 infections. ImmunoPrecise Antibodies using its proprietary B cell Select™ progressive single-cell interrogation technology and the DeepDisplay™ discovery platform to develop the vaccine. ImmunoPrecise's proprietary B cell Select™ platform which screens millions of cells, and facilitates diverse antibody identification, with low manipulation. The platform is species and tissue independent, which helps generate antibodies from samples not possible using other methods. The platform exploits an animal's immune repertoire, enabling screening of any protein class, complex therapeutic targets, post-translational modifications, and small molecules. Pre-clinical development for the prevention of COVID-2019 infections is underway in the US. Early research for the treatment of COVID-2019 infections is underway in the US.

As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections in USA (Injection).

Company Agreements

In June 2020, ImmunoPrecise Antibodies (IPA) and LiteVax entered a research and development agreement to conduct preclinical studies of IPA's SARS-CoV-2 vaccine candidates, co-formulated with LiteVax's adjuvant (LVA). Under the terms of the agreement, both companies will retain full rights to their respective proprietary assets and know-how used for the study. The preclinical studies of IPA's protein-based vaccine candidates that are formulated with LVA against SARS-CoV-2 infection in a swine model, will be completely funded by TRANSVAC2. Protein-based vaccine candidates will be supplied by ImmunoPrecise and LVA will be supplied by LiteVax. If the preclinical studies are successful, IPA and LiteVax may negotiate the terms for a preclinical study in a second animal model, and the details of the potential commercialisation of any resulting vaccine. Financial details of the agreement have not been disclosed. [1] [2]

Key Development Milestones

In December 2020, ImmunoPrecise and LiteVax announced the nomination of a lead vaccine for further preclinical evaluation and development based on results from their collaborative preclinical immunogenicity study. ImmunoPrecise and LiteVax selected the vaccine candidate following an assessment of the immunogenicity profiles of multiple SARS-CoV-2 vaccine candidates. The company also released the preclinical safety and immunogenicity data that demonstrated significant antibody responses towards the full SARS-Cov-2 spike timer following a single injection. Both the companies also anticipate initiating additional, parallel preclinical studies to evaluate the durability and efficacy of immune responses in large non-rodents, as well as in a SARS-CoV-2 Syrian hamster model [3] .

In September 2020, ImmunoPrecise and LiteVax announced that, both companies initiated pre-clinical trials focusing on the feasibility of a single-low-dose administration of coronavirus vaccine to assess the safety and tolerability of the vaccine formulations at Spain [4] .

Drug Properties & Chemical Synopsis

  • Route of administration Injection
  • Formulation unspecified
  • Class COVID-19 vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Download Data (CSV)
Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical USA Injection / unspecified ImmunoPrecise Antibodies 25 Sep 2020
COVID 2019 infections - - No development reported (Research) USA Injection / unspecified ImmunoPrecise Antibodies 28 Mar 2024

Commercial Information

Involved Organisations

Organisation Involvement Countries
ImmunoPrecise Antibodies Originator Canada
ImmunoPrecise Antibodies Owner Canada
TRANSVAC2 Funder
LiteVax BV Collaborator Netherlands

Scientific Summary

Adverse Events

In preclinical studies, low dose of the selected coronavirus vaccine candidate following a single injection showed no adverse effects for any of the treatment groups [3] .

Immunogenicity

In preclinical studies, immunisation of swine with a low dose of the selected candidate resulted in significant serum reactivities towards the SARS-CoV-2 spike protein segment. The combination with LiteVax's carbohydrate derivative-based adjuvant induced substantially higher immune responses, when compared to non-adjuvant formulations [3] .

Development History

Event Date Update Type Comment
28 Mar 2024 Phase Change - No development reported No recent reports of development identified for research development in COVID-2019-infections in USA (Injection) Updated 28 Mar 2024
14 Dec 2020 Scientific Update Immunogenicity and adverse event data from a preclinical studies in COVID-2019 infections released by ImmunoPrecise antibodies and LiteVax [3] Updated 17 Dec 2020
25 Sep 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in USA (Injection) [4] Updated 29 Sep 2020
31 Aug 2020 Trial Update ImmunoPrecise antibodies plans a preclinical trial for COVID-2019 infections (Prevention) in August 2020 [1] Updated 11 Sep 2020
22 Jun 2020 Licensing Status ImmunoPrecise antibodies and LiteVax agree to co-promote and co-develop Coronavirus vaccine for COVID-19 infections [1] Updated 11 Sep 2020
20 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (unspecified route) Updated 04 Mar 2020
20 Feb 2020 Phase Change Early research in COVID-2019-infections in USA (unspecified route) Updated 04 Mar 2020

References

  1. Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2. Internet-Doc 2020;.

    Available from: URL: https://www.immunoprecise.com/collaborative-covid-19-vaccine-project-between-immunoprecise-antibodies-europe-and-litevax-bv-funded-through-transvac2/

  2. Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2.

    Media Release

  3. ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate.

    Media Release

  4. ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top